Metabolic HealthMore Powerful GLP-1 Drugs Don't Mean More Side Effects, Major Analysis Finds
A systematic analysis of 38 placebo-controlled trials covering 16,660 people with type 2 diabetes compared all approved incretin mimetics — from older GLP-1 drugs like exenatide to the newer dual agonist tirzepatide. Researchers found enormous differences in how well these drugs lower blood sugar and body weight: HbA1c reductions ranged from 0.63% with lixisenatide to 1.79% with tirzepatide, and weight loss ranged from under 1 kg to nearly 10 kg. Surprisingly, the more potent agents did not cause significantly higher rates of nausea, vomiting, or diarrhea than their weaker counterparts, challenging the assumption that greater efficacy comes at the cost of worse tolerability.
